P&G Health Bolsters Commitment to "Total Body Health" at the 1st Middle East Whole Body Health Symposium' 2022 – Yahoo Finance

Share Article

Symposium attended by 13 090 Pharmacists & HCPs from across 111 countries featured sessions introducing new and innovative ways to support consumer health and well-being across multiple touchpoints
Leading global experts led sessions relevant to Total Body Health topics from Oral and General Health to Maternal Health and Non-Communicable Diseases
Ahead of World Pharmacists Day 2022, the Symposium highlighted the critical role of Pharmacists in timely diagnoses, education, and management
DUBAI, UAE, Sept. 26, 2022 /PRNewswire/ —  P&G Health renewed its commitment to holistically-driven “Total Body Health” at its first P&G Health Middle East Whole Body Health Symposium’ on September 23 & 24, 2022. This collaborative, professionally accredited virtual event brought together 13 090 diverse pharmacy professionals, stakeholders, and organizations representing more than 4 716 community pharmacy practice sites in 111 countries to share knowledge, expertise and build a community of healthcare professionals dedicated to better collective world health.
The pharmaceutical sector in the MENA region is estimated to reach around $60 billion by 2025. Aligning with the “Pharmacy united in action for a healthier world” theme of World Pharmacists Day on September 25, the Symposium underscored the role of pharmacists as frontrunners in enabling holistic health journeys for patients/consumers and a strong catalyst of transformation while pharmacies innovate as a one-stop shop for routine care. Pharmacists were spotlighted for their role in improving health outcomes by providing counsel on daily self-care habits, timely diagnoses, education, and management.
Dr Ashley Barlow, Senior Director, Medical & Technical Affairs, P&G Health – Asia Pacific, India, Middle East, and Africa said: “We are delighted to lead the first P&G Health Middle East Whole Body health Symposium and bring healthcare professionals and thought leaders together to create new conversations, scientific exchange and foster collaborations that drive meaningful impact within the holistic health economy. With growth opportunities in consumer health and wellness segments, P&G Health is demonstrating through focused and continued innovation how unlocking the power of well-informed health professionals can facilitate ‘Total Body Health’ in the region and beyond.”
With a commitment to improving the lives of the world’s consumers, P&G Health’s global and regional experts including Associate Professor Nadia Al Mazrouei, UAE, Professor Ibrahim A. Alsarra, PhD, Saudi Arabia and Dr. Samira Al-Osailan, Vice President of the Saudi Dental Association led an exclusive agenda covering a range of topics including Oral and General Health, Maternal Health and Non-Communicable Diseases. The interactive, virtual sessions highlighted the role of pharmacists within the holistic health journey and presented actionable updates pharmacists need to stay informed, deliver optimal care and improve quality of life of consumers.
Assoc. Prof Nadia Al Mazrouei, Pharmacy Practice and Pharmacotherapeutics, Sharjah University and a moderator at the summit said: “As healthcare systems continue to evolve, consumers have a heightened awareness of self-care. Pharmacists play a crucial role in the ongoing holistic health revolution as go-to resources for consumers to gain information and develop an understanding of complex conditions. We are pleased to partner with P&G Health to facilitate better healthcare outcomes and foster equity across diverse communities in the region and raise awareness of the role of pharmacists within holistic healthcare.”
P&G Health was honoured to partner with regional professional associations on this initiative creating a collaborative platform through which to engage and enable best practice sharing between academic, clinical and industry experts. The P&G Health Middle East Pharmacists Summit, that was organized by CAPP Events & Training, was accredited by local and international health authorities including Saudi Commission of Health Specialists and endorsed by EMROpharm and supported by International Pharmaceutical Federation (FIP)
Pharmacists in attendance at the Symposium had the opportunity to build their expertise and identify practical approaches to strengthen total body health with sessions covering oral care, heart, nerve and respiratory health, endocrinology, and pregnancy. They also had access to thought-provoking panels and discussions designed to empower pharmacists to learn, grow, and thrive in the ever-changing pharmacy sector.
For more information, please visit https://cappmea.com/whole-body-health
About P&G Health:
P&G Health, the health care division of P&G company, drives consumer-centric innovation to empower our consumers to live longer, healthier, and more vibrant lives. The P&G Health portfolio includes leading brands in Respiratory with Vicks® and Nasivin®, Pregnancy with Femibion® and Clearblue®, Oral Care with Crest® and Oral-B®, Vitamins and Minerals Supplementation with Bion3®, Seven Seas®, Evion® and Sangobion®, Digestive wellness with Metamucil®, Prilosec OTC®, Pepto Bismol® and Align®, Nerve Care with Neurobion® and Pain Relief with Dolo-Neurobion®.
About P&G Health Middle East:
P&G strives to improve the lives of 90 million consumers in the Arabian Peninsula & Levant region. Our portfolio consists of leading iconic brands such as Neurobion, Vicks, Seven Seas, and Femibion which have been trusted by patients & health care professionals for decades.
About Procter & Gamble:
P&G serves consumers around the world with one of the strongest portfolios of trusted, quality, leadership brands, including Always®, Ambi Pur®, Ariel®, Bounty®, Charmin®, Crest®, Dawn®, Downy®, Fairy®, Febreze®, Gain®, Gillette®, Head & Shoulders®, Lenor®, Olay®, Oral-B®, Pampers®, Pantene®, SK-II®, Tide®, Vicks®, and Whisper®. The P&G community includes operations in approximately 70 countries worldwide.
Photo – https://mma.prnewswire.com/media/1907357/Body_Health_Symposium.jpg
View original content to download multimedia:https://www.prnewswire.com/news-releases/pg-health-bolsters-commitment-to-total-body-health-at-the-1st-middle-east-whole-body-health-symposium-2022-301633107.html
Axsome Therapeutics' solid gains of 42% this year came with the hope that its two new products would bring in plenty of revenue in the next few years. Last month, the U.S. Food and Drug Administration (FDA) approved its drug Auvelity for treating major depressive disorder (MDD).
Shares of Avidity Biosciences Inc. tumbled 23.7% in premarket trading on Tuesday after the company said the Food and Drug Administration placed a partial clinical hold on new enrollment in a Phase 1/2 clinical trial trial evaluating a new treatment for myotonic dystrophy type 1, a progressive neuromuscular disease. Avidity said the partial hold is the result of a serious adverse event reported in one patient. The adverse event "driving the partial hold is currently undisclosed, but we think it i
The pharmaceutical company allegedly used speaking and consulting fees to persuade doctors to prescribe its multiple sclerosis drugs.
Shares of Eli Lilly (NYSE: LLY) recently ticked higher in response to encouraging words from a Wall Street analyst who follows the pharmaceutical industry. Colin Bristow at UBS, an investment bank, thinks this is the most attractive pharma stock you can buy right now. Is Bristow right about Eli Lilly?
Is Pfizer stock a sell on an expected decline for Covid vaccine sales in the third quarter? Is PFE stock now a sell?
The FDA Oncologic Drugs Advisory Committee votes against Spectrum's (SPPI) poziotinib for treating non-small cell lung cancer in previously treated patients with HER2 exon 20 mutations. Stock down.
The FDA has granted 510(k) clearance to Pulse Biosciences Inc's (NASDAQ: PLSE) CellFX System, expanding the indication for use to include the treatment of sebaceous hyperplasia in patients with Fitzpatrick skin types I-III. Sebaceous hyperplasia is a very common non-contagious skin condition. It causes small bumps on the skin. These bumps are often skin-colored and can be smooth, slightly uneven, and coarse. This specific indication clearance enhances the CellFX System's general indication FDA c
Listeriosis kills around 200 people every year, according to the CDC
With the Annual Enrollment Period Coming Up, Author and Medicare Expert Ari Parker Shares His Top Tips for Navigating Medicare Decisions
Here's where you can look for an available appointment or join a waitlist for a vaccine.
Healthcare has been top of mind for a lot of people since the COVID-19 pandemic began over two years ago. Here are the five states with the lowest average healthcare costs in the U.S. It has the cheapest healthcare costs of anywhere in the U.S., with average prices about 27.3% below the national average.
Tonight, Jupiter will be the closest it’s been to Earth decades, and if the sky’s clear, you should be able to see the gas giant and some of its moons. In health news, Pfizer wants the FDA to authorize the omicron booster shot for kids ages 5 to 11. Welcome to Overnight Health Care, where…
It's risky, and you'll need to wait a while for a payoff, assuming the stars align for there to be one.
The former Trump adviser attacked John Fetterman for flying a marijuana flag.
Photo Illustration by Thomas Levinson/The Daily Beast/GettyScientists have identified a molecule that just loves SARS-CoV-2, the virus that causes COVID-19. It loves it so much that it “hugs” it, practically to death—binding so tightly to the virus that the virus can’t infect our cells.The discovery of this molecule, a so-called “HR2 peptide,” is a big deal. It could form the basis of a new kind of antiviral drug. One that should work not only on current variants of the novel-coronavirus, but fu
Three Motley Fool contributors have joined this roundtable to scour the market for some exciting initial public offerings (IPOs) in the healthcare field. Alex Carchidi (Amylyx Pharmaceuticals): Amylyx is worth owning because there's a solid chance it'll soon commercialize the first treatment for amyotrophic lateral sclerosis (ALS) that prolongs survival time while also slowing the disease's progression. Its medicine, AMX0035, has been approved for sale in Canada since late July, and regulators at the U.S. Food and Drug Administration will weigh in on the company's application for commercialization on Sept. 29.
Going out more is always best. Your pup will thank you.
The Biden administration is laying out its plan to meet an ambitious goal of ending hunger in the U.S. by 2030, including expanding monthly benefits that help low-income Americans buy food. The administration, in a plan released Tuesday, is also seeking to increase healthy eating and physical activity so that fewer people are afflicted with diabetes, obesity, hypertension and other diet-related diseases. “The consequences of food insecurity and diet-related diseases are significant, far reaching, and disproportionately impact historically underserved communities,” Biden wrote in a memo outlining the White House strategy.
By 2025, the U.S. is estimated to have a shortage of 446,000 home health aides, 95,000 nursing assistants, 98,700 medical and lab techs, and more than 29,000 nurse practitioners.
Remote-work wars, crisis-level traffic deaths and STD infections, do-gooder fatigue, and mental health fears. Welcome to post-pandemic life.


You might also like

Surviving 2nd wave of corona

Surviving The 2nd Wave of Corona

‘This too shall pass away’ this famous Persian adage seems to be defeating us again and again in the case of COVID-19. Despite every effort